Treatment Options for Nephrogenic Systemic Fibrosis
When it comes to treating nephrogenic systemic fibrosis (NSF), doctors typically recommend various supportive treatments. These include physical therapy and pain medications, which aim to preserve functionality, prevent joint contractures, and reduce rigidity.
Plasmapheresis, a relatively new treatment method, is similar to dialysis but involves a kidney transplant. By filtering the blood and removing antibodies in plasma that could potentially cause rejection of the kidney, doctors can make it safe for individuals to undergo a kidney transplant even from donors with incompatible blood types. This innovative procedure effectively addresses the challenges associated with blood type incompatibility, thereby reducing the time required to find a suitable kidney donor.
In addition to plasmapheresis, other treatments that may help alleviate or delay NSF symptoms include intravenous immunoglobulin therapy and immune modulators. Intravenous immunoglobulin therapy involves the use of special antibodies known as immunoglobulins, which suppress cytokines and other inflammatory mediators responsible for the systemic inflammation observed in individuals with NSF.
Moreover, phototherapy, which entails exposing the skin to ultraviolet light (UVA rays), has also shown potential in managing the skin manifestations associated with NSF.
It is important to note that all of these treatments are still considered experimental, as there is currently no proven treatment for NSF.
Can Children Develop Nephrogenic Systemic Fibrosis (NSF)?
In rare cases, children can develop nephrogenic systemic fibrosis (NSF), although it is more commonly observed in adults. However, there have been a few reported cases of babies who have received Gadolinium-based contrast agents (GBCA) due to having immature kidneys or congenital heart disease. It is important to note that not all babies and young children requiring MRI scans with GBCA develop signs of NSF.
Researchers hypothesize that infants may possess some level of resistance to GBCA, potentially linked to their underdeveloped immune systems and limited inflammatory response.